EUVIMEDOpdag EUVIMED
Open access

Economic Burden of Type 1 Diabetes in France

Emmanuel Cosson iD, Corinne Emery iD, Elodie Torreton, Bruno Detournay iD, Bruno Verges iD, Pierre-Yves Benhamou iD, Maxime Brule iD, Laura Sablone iD, Guy Fagherazzi iD, Jean Pierre Riveline iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71103 ↗

At a glance

Journal article in Diabetes, Obesity and Metabolism, 2026. Written by Emmanuel Cosson and 9 co-authors. Institution: Department of Endocrinology-Diabetology-Nutrition, AP-HP, Avicenne Hospital, Université Paris 13, Sorbonne Paris Cité, CRNH-IdF, CSO-IdF Nord, Bobign…. Major MEDLINE topics: Diabetes Mellitus, Type 1, Cost of Illness, Health Care Costs. Cited 1 times so far (Crossref); 29 references. The full text is freely available in PubMed Central. Funded by: Foundation Francophone pour la Recherche sur le Diabète (FFRD), Société Francophone du Diabète (SFD), iCare4CVD.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aim

To estimate the societal costs of Type 1 diabetes (T1D) in France, including direct and indirect costs. Materials and Methods We conducted a descriptive retrospective cross‐sectional study on all adult patients (aged 18 and over) with T1D identified in the SFDT1 cohort and compared them to a matched cohort of patients without diabetes considering age, gender, deprivation status and geographical area. An Insurance claim data analysis was conducted for the year 2023 individually and then extrapolated to all of France. Costs were broken down by expense categories and insulin delivery devices.

Results

The average individual societal cost of T1D in France in 2023 compared with the absence of diabetes was estimated at €9940 (€9340 when considering direct costs only). Nearly half of the identified costs were attributable to the use of medical devices. An analysis stratifying patients by treatment modality (closed‐loop, pump or multiple daily injections) highlighted the significant costs associated with the use of the most advanced technologies for delivering insulin (average costs were respectively €13 557, €11 062, and €7004, respectively). The total cost of T1D in France was estimated at between €1.59 and €1.79 billion in 2023 excluding undiagnosed cases and premature mortality associated with the disease.

Conclusions

Our results suggest that the most advanced insulin delivery devices have a significant short‐term economic impact. Although this paper does not cover the research, model‐based studies do suggest that there are some advantages to using such devices, including potential future savings due to lower complication rates.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 1Cost of IllnessHealth Care CostsHumansFranceFemaleRetrospective StudiesCross-Sectional StudiesAdultMaleInsulinInsulin Infusion SystemsHypoglycemic AgentsMiddle AgedYoung AdultAdolescent

Author keywords

Type 1 diabetesdatabase researchhealth economicsinsulin therapy

Substances

InsulinHypoglycemic Agents

Authors and institutions

  • Department of Endocrinology-Diabetology-Nutrition, AP-HP, Avicenne Hospital, Université Paris 13, Sorbonne Paris Cité, CRNH-IdF, CSO-IdF Nord, Bobigny, France.
  • Center of Research in Epidemiology and StatisticS (CRESS), Nutritional Epidemiology Research Team (EREN), Université Sorbonne Paris Nord and Université Paris Cité, INSERM, INRAE, CNAM, Bobigny, France.
  • Cemka, Bourg-la-Reine, France.
  • Department of Endocrinology, Diabetology and Metabolic Diseases, CHU Dijon, Dijon, France.
  • INSERM LNC-UMR1231, University of Burgundy, Dijon, France.
  • Department of Endocrinology, Grenoble University Hospital, Grenoble Alpes University, INSERM U1055, LBFA, Grenoble, France.

ORCID profiles: Emmanuel Cosson, Corinne Emery, Bruno Detournay, Bruno Verges, Pierre-Yves Benhamou, Maxime Brule, Laura Sablone, Guy Fagherazzi, Jean Pierre Riveline

Funding

  • Foundation Francophone pour la Recherche sur le Diabète (FFRD)
  • Société Francophone du Diabète (SFD)
  • iCare4CVD
  • Aide aux Jeunes Diabétiques (AJD)
  • Fédération Française des Diabétiques (FFD)
  • Lilly
  • Abbott
  • Air Liquide Healthcare

Cite

APA

Cosson, E., Emery, C., Torreton, E., Detournay, B., Verges, B., Benhamou, P. Y., Brule, M., Sablone, L., Fagherazzi, G., & Riveline, J. P. (2026). Economic Burden of Type 1 Diabetes in France. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71103

Vancouver

Cosson E, Emery C, Torreton E, Detournay B, Verges B, Benhamou PY, et al. Economic Burden of Type 1 Diabetes in France. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71103

BibTeX
@article{Cosson2026,
  author = {Cosson, Emmanuel and Emery, Corinne and Torreton, Elodie and Detournay, Bruno and Verges, Bruno and Benhamou, Pierre-Yves and Brule, Maxime and Sablone, Laura and Fagherazzi, Guy and Riveline, Jean Pierre},
  title = {Economic Burden of Type 1 Diabetes in France},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71103}
}
Start for free →